{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-015206","form_type":"8-K","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.521352+00:00","generated_at":"2026-06-16T00:37:00.751550+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Vanda Q1 2023 revenue $62.5M (+4% YoY); net income $3.3M vs loss","bullets":["Net product sales: HETLIOZ $39.6M (+7% YoY), Fanapt $22.9M (-1% YoY).","Diluted EPS $0.06 vs ($0.11) in prior year; cash $501.5M (+15% YoY).","Expects sNDA for Fanapt in bipolar I disorder and NDA for tradipitant in gastroparesis in Q2 2023.","At-risk generic HETLIOZ launch in U.S. likely to cause significant future sales decline; no 2023 guidance provided.","Awaiting Federal Circuit ruling on HETLIOZ patent appeal; won FOIA lawsuit against FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-015206","json":"https://secwatch.observer/filing/0001628280-23-015206.json","markdown":"https://secwatch.observer/filing/0001628280-23-015206.md","text":"https://secwatch.observer/filing/0001628280-23-015206.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000162828023015206/0001628280-23-015206-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000162828023015206/vnda-20230503.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T00:37:00.751550+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b024a551a476b56514636e5224bf61ed41550369","claim":"Vanda Pharmaceuticals Inc. reported the first quarter ended March 31, 2023 results: revenue $62.5 million, net income $3.3 million, EPS diluted net income per share was $0.06.","evidence_excerpt":"set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- Vanda Pharmaceuticals Reports First Quarter 2023 Financial Results • Q1 2023 total revenues were $62.5 million • Vanda provides update on three upcoming regulatory submissions WASHINGTON – May 3, 2023 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1347178/000162828023015206/0001628280-23-015206-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$62.5 million"},{"label":"Net income","value":"$3.3 million"},{"label":"EPS","value":"diluted net income per share was $0.06"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}